Discovery of Tumor, Treatment Response, and Systems-based EVP Signatures

作为一名执业的放射肿瘤学家，我试图将我的实验室和临床工作整合到一个有凝聚力的转换研究计划中，我的临床实践重点是治疗转移性癌症患者，放射可能对他们有利。在过去的一年里，我在NCI放射肿瘤科创建了颅外晚期恶性肿瘤治疗(团队)小组，我们正在制定旨在改善对晚期恶性肿瘤患者的评估和治疗的方案。我与团队的一个主要工作重点是液体活检，目前的一个主要研究目标是确定液体活检或生物液EVP图谱与治疗反应相关。该项目的转化研究工作遵循双管齐下的方法：1)与NIH的内科和外科肿瘤学同事合作，作为合作者现有方案的一部分，研究EVP作为肿瘤状态的生物标记物；2)开发新的临床方案，以更有凝聚力和信息量的方式从这一患者群体中捕获信息和样本。这两种方法都得到了CCR的临床翻译任务和翻译纳米生物学科正在进行的EVP谱系研究的基础科学工作的支持和支持。

As a practicing radiation oncologist, seeking to integrate my laboratory and clinical efforts into a cohesive translational research program, I have focused my clinical practice on the care of patients with metastatic cancers, for whom radiation may be beneficial. In the past year, I created the Treatment of Extra-cranial Advanced Malignancies (TEAM) group in the NCI Radiation Oncology Branch, and we are developing protocols designed to improve the assessment and treatment of patients with advanced malignancies. A major focus of my work with the TEAM group is liquid biopsies, and a major research aim currently is to determine what liquid biopsy or biofluid EVP profiles correlate with responses to treatment. The translational research efforts of this project are following a two-pronged approach: 1) collaborating with medical and surgical oncology colleagues at NIH to investigate EVPs as biomarkers for tumor status as part of those collaborators' existing protocols, and 2) developing new clinical protocols to capture information and samples from this patient population in a more cohesive and informative manner. Both of these approaches are supported by and provide support to the CCR's clinical translational mission and the basic scientific work ongoing in the Translational Nanobiology Section for the study of EVP repertoires.